- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00656396
Point of Care Coagulation Testing in Patients Undergoing Major Surgery (POC-OP)
7. september 2015 oppdatert av: University of Bern
Does Point of Care Coagulation Testing Reduce the Transfusion of Non-erythrocyte Blood Products in Patients Undergoing Major Surgery? A Randomized-Controlled Trial
Bleeding is a frequent complication during surgery.
The peri-operative administration of blood products, including packed red blood cells, thrombocytes and fresh frozen plasma (FFP), is often deemed necessary.
Therefore the transfusion of allogenic blood products mandates strategies to optimize the clinical decision to transfuse.
The decision to administer FFP is usually made in the absence of any data.
Point of care testing of prothrombin time ensures that a major parameter of coagulation is readily available.
The test is fast, easy to perform, inexpensive and may enable physicians to rationally determine the need for FFP.
Objective of the study is to determine the effectiveness of point of care coagulation testing of prothrombin time to reduce the administration of FFP.
Studieoversikt
Status
Fullført
Forhold
Detaljert beskrivelse
Background: Bleeding is a frequent complication during surgery.
The peri-operative administration of blood products, including packed red blood cells, thrombocytes and fresh frozen plasma (FFP), is often deemed necessary.
Beside the expenses of blood products these products carry risks of infection, allergic reaction and immune-modulation.
Therefore the transfusion of allogenic blood products mandates strategies to optimize the clinical decision to transfuse.
Bleeding during surgery is a dynamic process; it can happen within minutes and result not only in major blood loss, but also in coagulation aberrations.
The indication for a transfusion should be based on reliable coagulation studies.
Traditional coagulation studies require up to 1 hour.
Therefore, the decision to administer FFP is usually made in the absence of any data.
Point of care testing of prothrombin time ensures that a major parameter of coagulation is readily available in the operation theatre within 3 minutes.
It is fast, easy to perform, inexpensive and may enable physicians to rationally determine the need for FFP.
Objective: To determine the effectiveness of point of care coagulation testing of prothrombin time to reduce the administration of FFP.
Methods: Patient and assessor blind, single center randomized controlled parallel group trial in 220 patients aged between 18 and 90 years undergoing major surgery (any type, except cardiac surgery and liver transplant) with an estimated blood loss during surgery exceeding 20% of the calculated normal total blood volume or a requirement of FFP according to the judgment of treating surgeons or anesthesiologists.
Patients will be randomized to usual care plus point of care coagulation testing or usual care alone without point of care testing.
Primary endpoint will be the relative risk to receive any FFP peri-operatively.
Significance: Point of care coagulation testing in the operation theatre may reduce the administration of fresh frozen plasma considerably, which in turn may decrease costs and complications usually associated with the administration of allogenic blood products.
Studietype
Intervensjonell
Registrering (Faktiske)
228
Fase
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Bern, Sveits, 3010
- University Hospital Bern
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 90 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Age between 18 and 90 years
- Major surgery
- Estimated blood loss during surgery > 20% of individual blood volume of 70ml per kg body weight
- Patients requiring FFP
Exclusion Criteria:
- Known hereditary coagulopathy
- Liver transplant
- Cardiac surgery
- Pregnancy
- Preoperative hemoglobin <100g/l
- Abnormal coagulation studies before surgery
- Active treatment with drugs inhibiting coagulation or platelet function
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Kontroll
Standard pleie
|
Standard care
|
|
Eksperimentell: Intervention
Point of care monitoring used
|
Coagucheck XS Plus® is used for intraoperative measurement of Prothrombin time
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
The relative risk to receive any FFP peri-operatively.
Tidsramme: at post-operative discharge from hospital, estimated to be about 5 days after randomisation
|
at post-operative discharge from hospital, estimated to be about 5 days after randomisation
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Number of units of FFP received between randomization and post-operative discharge from hospital
Tidsramme: at post-operative discharge from hospital, estimated to be about 5 days after randomisation
|
at post-operative discharge from hospital, estimated to be about 5 days after randomisation
|
|
The relative risk of major in-hospital bleeding defined as bleeding event requiring an extension of hospitalization, reoperation due to bleeding, bleeding resulting in hemorrhagic shock or death
Tidsramme: at post-operative discharge from hospital, estimated to be about 5 days after randomisation
|
at post-operative discharge from hospital, estimated to be about 5 days after randomisation
|
|
The relative risk of an APTC event (non-fatal myocardial infarction, non-fatal stroke, cardiovascular death, or death of unknown cause) between randomization and post-operative discharge from hospital
Tidsramme: at post-operative discharge from hospital, estimated to be about 5 days after randomisation
|
at post-operative discharge from hospital, estimated to be about 5 days after randomisation
|
|
The relative risk of overall mortality between randomization and post-operative discharge from hospital
Tidsramme: at post-operative discharge from hospital, estimated to be about 5 days after randomisation
|
at post-operative discharge from hospital, estimated to be about 5 days after randomisation
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Studieleder: Robert Greif, MD MME, Departement of Anesthesiology and Pain Therapy, Bern University Hospital
- Hovedetterforsker: Natalie Urwyler, MD, Bern University Hospital
- Studiestol: Peter Jüni, PD Dr med, CTU Bern, Bern University Hospital, and Institute of Social and Preventive Medicine, University of Bern
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. mai 2008
Primær fullføring (Faktiske)
1. september 2011
Studiet fullført (Faktiske)
1. september 2011
Datoer for studieregistrering
Først innsendt
7. april 2008
Først innsendt som oppfylte QC-kriteriene
10. april 2008
Først lagt ut (Anslag)
11. april 2008
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
9. september 2015
Siste oppdatering sendt inn som oppfylte QC-kriteriene
7. september 2015
Sist bekreftet
1. september 2015
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- KEK 232_06
- 232_06 (Annen identifikator: KEK)
- 3200B0_122461 (Annet stipend/finansieringsnummer: SNF)
- 1295 (Inselspital)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .